Hari K Narayan
Overview
Explore the profile of Hari K Narayan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
328
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Lee K, Lindenfeld L, Echevarria M, Hsu J, Wong F, Narayan H, et al.
Int J Cardiol
. 2023 Mar;
380:40-46.
PMID: 36958393
Background: Tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) have revolutionized the treatment of metastatic renal cell carcinoma (mRCC). Emerging data suggest that these agents can result in clinically...
12.
Narayan H, Lizcano A, Lam-Hine T, Ulloa-Gutierrez R, Bainto E, Garrido-Garcia L, et al.
J Pediatr
. 2023 Feb;
263:113346.
PMID: 36775190
Objectives: To describe the clinical presentation, management, and outcomes of Kawasaki disease (KD) in Latin America and to evaluate early prognostic indicators of coronary artery aneurysm (CAA). Study Design: An...
13.
Li H, Chen Z, Kahn A, Kligerman S, Narayan H, Contijoch F
Front Cardiovasc Med
. 2023 Jan;
9:1009445.
PMID: 36588550
Introduction: 4D cardiac CT (cineCT) is increasingly used to evaluate cardiac dynamics. While echocardiography and CMR have demonstrated the utility of longitudinal strain (LS) measures, measuring LS from cineCT currently...
14.
Demissei B, Vedage N, Hubbard R, Smith A, Chung J, Lefebvre B, et al.
JACC CardioOncol
. 2022 Nov;
4(4):552-554.
PMID: 36444221
No abstract available.
15.
Narayan H, Sheline K, Wong V, Kuo D, Choo S, Yoon J, et al.
Pediatr Blood Cancer
. 2022 Nov;
70(2):e30059.
PMID: 36385736
We sought to examine cardiovascular toxicities associated with tyrosine kinase inhibitors in pediatrics. We examined 1624 pediatric adverse events with imatinib, dasatinib, sorafenib, pazopanib, crizotinib, and ruxolitinib reported to the...
16.
Chen Z, Contijoch F, Colvert G, Manohar A, Kahn A, Narayan H, et al.
Front Cardiovasc Med
. 2022 Aug;
9:919751.
PMID: 35966529
Background: The presence of left ventricular (LV) wall motion abnormalities (WMA) is an independent indicator of adverse cardiovascular events in patients with cardiovascular diseases. We develop and evaluate the ability...
17.
Hartman S, Chen R, Tam R, Narayan H, Natarajan L, Liu L
JMIR Mhealth Uhealth
. 2022 Jun;
10(6):e37086.
PMID: 35771607
Background: There has been a rapid increase in the use of commercially available activity trackers, such as Fitbit, in physical activity intervention research. However, little is known about the long-term...
18.
Narayan H, Getz K, Leger K
Hematology Am Soc Hematol Educ Program
. 2021 Dec;
2021(1):368-375.
PMID: 34889355
Anthracycline chemotherapy remains an integral component of modern pediatric acute myeloid leukemia (AML) regimens and is often delivered at high doses to maximize cancer survival. Unfortunately, high-dose anthracyclines are associated...
19.
Narezkina A, Narayan H, Zemljic-Harpf A
Clin Sci (Lond)
. 2021 May;
135(10):1311-1332.
PMID: 34047339
Anthracyclines are effective chemotherapeutic agents, commonly used in the treatment of a variety of hematologic malignancies and solid tumors. However, their use is associated with a significant risk of cardiovascular...
20.
Krishnan S, Narayan H, Freedman G, Plastaras J, Maity A, Demissei B, et al.
Int J Radiat Oncol Biol Phys
. 2020 Nov;
109(4):946-952.
PMID: 33223046
Purpose: The effects of thoracic radiation therapy (RT) on physical functioning and quality of life (QoL) are incompletely defined. We determined the associations between thoracic RT dose volume metrics, physical...